Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
End Zoster-J study of Shingrix immune response in Japanese rheumatoid arthritis patients on methotrexate and/or upadacitinib
jRCTs051220105Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Zoster vaccine recombinant, upadacitinib and methotrexate in herpes zoster (HZ) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Immunogenicity 4 weeks after second Shingrix dose. Started Dec 2022; status: active, not recruiting.
02
Drugs
Zoster vaccine recombinantupadacitinibmethotrexate
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on jRCTs051220105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220105.